Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: Results of two phase I studies

L. Miglietta, C. Marenghi, R. Nizzo, G. Foglia, N. Ragni, Francesco Boccardo

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Study Purposes: To determine the maximum-tolerated dose (MTD) of paclitaxel administered by 72-hour continuous infusion followed by bolus intravenous ifosfamide on days 4 and 5 or epirubicin on day 4, every 21 days. To assess the toxicity and preliminary activity in patients with advanced refractory solid tumors. Patients and Methods: Sixteen patients with progressive disease after standard chemotherapy for advanced disease were treated with the combination paclitaxel-ifosfamide and 10 patients with the combination paclitaxel-epirubicin. Results: In the first phase I study the MTDs were: paclitaxel 135 mg/m 2 and ifosfamide 2.5 mg/m 2/day; hematologic toxicity was the dose-limiting toxicity (DLT) during the first cycle of therapy at dose level 4. Paclitaxel administered at 135 mg/m 2 and epirubicin 50 mg/m 2 were the MTDs in the second phase I study; grade 4 stomatitis was the DLT of this combination. Conclusions: Paclitaxel by 72-hour continuous infusion followed by bolus ifosfamide was a manageable regimen with an acceptable hematologic toxicity in the absence of neurotoxicity. Preliminary activity of this combination was encouraging in a group of patients with ovarian cancer. The optimal way to combine paclitaxel and epirubicin and the best schedule relative to such a long paclitaxel infusion time in this combination regimen remain to be determined.

Original languageEnglish
Pages (from-to)116-122
Number of pages7
JournalOncology
Volume60
Issue number2
DOIs
Publication statusPublished - 2001

Fingerprint

Epirubicin
Ifosfamide
Paclitaxel
Stomatitis
Maximum Tolerated Dose
Ovarian Neoplasms
Appointments and Schedules
Drug Therapy

Keywords

  • Epirubicin
  • Ifosfamide
  • Infusion, continuous
  • Paclitaxel
  • Phase I

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin : Results of two phase I studies. / Miglietta, L.; Marenghi, C.; Nizzo, R.; Foglia, G.; Ragni, N.; Boccardo, Francesco.

In: Oncology, Vol. 60, No. 2, 2001, p. 116-122.

Research output: Contribution to journalArticle

Miglietta, L. ; Marenghi, C. ; Nizzo, R. ; Foglia, G. ; Ragni, N. ; Boccardo, Francesco. / Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin : Results of two phase I studies. In: Oncology. 2001 ; Vol. 60, No. 2. pp. 116-122.
@article{ff3b005bf13b4af3b198cbb179293453,
title = "Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: Results of two phase I studies",
abstract = "Study Purposes: To determine the maximum-tolerated dose (MTD) of paclitaxel administered by 72-hour continuous infusion followed by bolus intravenous ifosfamide on days 4 and 5 or epirubicin on day 4, every 21 days. To assess the toxicity and preliminary activity in patients with advanced refractory solid tumors. Patients and Methods: Sixteen patients with progressive disease after standard chemotherapy for advanced disease were treated with the combination paclitaxel-ifosfamide and 10 patients with the combination paclitaxel-epirubicin. Results: In the first phase I study the MTDs were: paclitaxel 135 mg/m 2 and ifosfamide 2.5 mg/m 2/day; hematologic toxicity was the dose-limiting toxicity (DLT) during the first cycle of therapy at dose level 4. Paclitaxel administered at 135 mg/m 2 and epirubicin 50 mg/m 2 were the MTDs in the second phase I study; grade 4 stomatitis was the DLT of this combination. Conclusions: Paclitaxel by 72-hour continuous infusion followed by bolus ifosfamide was a manageable regimen with an acceptable hematologic toxicity in the absence of neurotoxicity. Preliminary activity of this combination was encouraging in a group of patients with ovarian cancer. The optimal way to combine paclitaxel and epirubicin and the best schedule relative to such a long paclitaxel infusion time in this combination regimen remain to be determined.",
keywords = "Epirubicin, Ifosfamide, Infusion, continuous, Paclitaxel, Phase I",
author = "L. Miglietta and C. Marenghi and R. Nizzo and G. Foglia and N. Ragni and Francesco Boccardo",
year = "2001",
doi = "10.1159/000055307",
language = "English",
volume = "60",
pages = "116--122",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "2",

}

TY - JOUR

T1 - Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin

T2 - Results of two phase I studies

AU - Miglietta, L.

AU - Marenghi, C.

AU - Nizzo, R.

AU - Foglia, G.

AU - Ragni, N.

AU - Boccardo, Francesco

PY - 2001

Y1 - 2001

N2 - Study Purposes: To determine the maximum-tolerated dose (MTD) of paclitaxel administered by 72-hour continuous infusion followed by bolus intravenous ifosfamide on days 4 and 5 or epirubicin on day 4, every 21 days. To assess the toxicity and preliminary activity in patients with advanced refractory solid tumors. Patients and Methods: Sixteen patients with progressive disease after standard chemotherapy for advanced disease were treated with the combination paclitaxel-ifosfamide and 10 patients with the combination paclitaxel-epirubicin. Results: In the first phase I study the MTDs were: paclitaxel 135 mg/m 2 and ifosfamide 2.5 mg/m 2/day; hematologic toxicity was the dose-limiting toxicity (DLT) during the first cycle of therapy at dose level 4. Paclitaxel administered at 135 mg/m 2 and epirubicin 50 mg/m 2 were the MTDs in the second phase I study; grade 4 stomatitis was the DLT of this combination. Conclusions: Paclitaxel by 72-hour continuous infusion followed by bolus ifosfamide was a manageable regimen with an acceptable hematologic toxicity in the absence of neurotoxicity. Preliminary activity of this combination was encouraging in a group of patients with ovarian cancer. The optimal way to combine paclitaxel and epirubicin and the best schedule relative to such a long paclitaxel infusion time in this combination regimen remain to be determined.

AB - Study Purposes: To determine the maximum-tolerated dose (MTD) of paclitaxel administered by 72-hour continuous infusion followed by bolus intravenous ifosfamide on days 4 and 5 or epirubicin on day 4, every 21 days. To assess the toxicity and preliminary activity in patients with advanced refractory solid tumors. Patients and Methods: Sixteen patients with progressive disease after standard chemotherapy for advanced disease were treated with the combination paclitaxel-ifosfamide and 10 patients with the combination paclitaxel-epirubicin. Results: In the first phase I study the MTDs were: paclitaxel 135 mg/m 2 and ifosfamide 2.5 mg/m 2/day; hematologic toxicity was the dose-limiting toxicity (DLT) during the first cycle of therapy at dose level 4. Paclitaxel administered at 135 mg/m 2 and epirubicin 50 mg/m 2 were the MTDs in the second phase I study; grade 4 stomatitis was the DLT of this combination. Conclusions: Paclitaxel by 72-hour continuous infusion followed by bolus ifosfamide was a manageable regimen with an acceptable hematologic toxicity in the absence of neurotoxicity. Preliminary activity of this combination was encouraging in a group of patients with ovarian cancer. The optimal way to combine paclitaxel and epirubicin and the best schedule relative to such a long paclitaxel infusion time in this combination regimen remain to be determined.

KW - Epirubicin

KW - Ifosfamide

KW - Infusion, continuous

KW - Paclitaxel

KW - Phase I

UR - http://www.scopus.com/inward/record.url?scp=0035085689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035085689&partnerID=8YFLogxK

U2 - 10.1159/000055307

DO - 10.1159/000055307

M3 - Article

C2 - 11244325

AN - SCOPUS:0035085689

VL - 60

SP - 116

EP - 122

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 2

ER -